neonatal opioid withdrawal. According to the Tennessee Department of Health's 2015 NAS surveillance report, more than half of cases statewide were attributable to supervised opioid replacement therapy. 13 These data are consistent with earlier sources that estimated NAS prevalence at 48 to 95% in neonates born to women in opioid maintenance treatment. 14, 15 Therefore, care models focused on infants born to mothers in recovery may be able to address a significant proportion of NAS cases. The conventional approach to managing NAS holds great challenges. No formal national guidelines for managing NAS yet exist, [16] [17] [18] but standard practice is to delay pharmacotherapy until a newborn displays sufficient objective signs and symptoms to justify treatment. 16, [19] [20] [21] This practice is based on several influences: NAS signs vary considerably and depend on several factors; [22] [23] [24] some infants may be adequately managed with nonpharmacologic care; 21 pharmacotherapy is typically administered only in high-acuity settings; 3 withdrawal is believed to be a self-limited process and has undefined long-term morbidities; 21 and studies suggest that prolonged fetal opioid exposure may cause harm. [25] [26] [27] [28] [29] [30] [31] In past decades, developing recommendations for pain management in neonates was similarly challenging. Pain symptoms in neonates are likewise nonspecific and vary considerably. There is no way to define the degree of pain that specific minor or major procedures will cause for a specific infant. However, research now supports the concept that pain experiences in neonates have the potential to cause harm, and the prevention and effective management of pain should be a goal of those caring for at-risk neonates. 32, 33 Because neurologic pathways for pain and withdrawal are similar, methods for managing NAS should achieve a similar goal. New models for treating confirmed NAS have been described that support expanding beyond conventional approaches. Patrick et al reported that methadone as initial treatment was associated with reduced hospital stay and duration of opioid therapy. 17 Backes et al demonstrated that a combined inpatient and outpatient treatment model reduces hospital stay and costs. 34 Johnston et al recommended methadone for pharmacologic treatment and outlined a standardized approach for inpatient care and outpatient weaning. 35 A model of prevention has not yet been explored. Hudak et al described the concept that "each clinical unit can establish a threshold level of cumulative [iatrogenic] exposure to opioids… above which drug dependency can be expected to occur with a likelihood that justifies anticipatory initiation of a weaning protocol." 21 In the same way, continuous fetal opioid exposure due to placental transfer of maternal long-acting opioid therapy in late gestation may also justify initiation of a weaning protocol immediately after birth. According to Hall's multicenter cohort study of outcomes related to NAS, the mean onset of symptoms was 46.1 hours of age, 3 which is consistent with other reports in the literature. [19] [20] [21] [36] [37] [38] At its peak, withdrawal is difficult to manage. By the time symptoms are controlled with pharmacotherapy, significant suffering and physical effects have often already occurred. These are well-documented to include excessive weight loss, feeding problems, self-inflicted excoriations, perianal maceration, vomiting, diarrhea, dehydration, and disruption of bonding and breast-feeding. 19, 21, 39, 40 Supportive therapies such as high-calorie feedings, intravenous fluids, treatments for perianal skin breakdown, therapies for hypertonicity, and disorganized feeding patterns may be needed to reverse the physical effects that occurred while waiting for enough objective evidence to rationalize pharmacotherapy. If withdrawal leads to newborn fever, additional blood work, procedures, and intravenous antibiotic treatment may be added. Therefore, delayed treatment may contribute to longer hospitalization, and medical complications of withdrawal must be addressed. The objective of this study was to describe medical, safety, and health care utilization outcomes associated with an early treatment model for neonatal opioid withdrawal.
Patients and Methods
This study is a descriptive analysis of newborns at high risk for opioid withdrawal who were treated with early methadone (within 48 hours) in a level I newborn care setting during 2006 to 2014. The study hospital is a large, regional perinatal referral center containing 710 beds with an average annual volume of 5,221 births from 2006 to 2014. This hospital is part of a public, not-for-profit academic health care delivery system. Approval from institutional review board was obtained prior to the study. Data collection was performed through data extraction from electronic medical records and direct chart review. All data were abstracted by a trained research assistant. The standard definition for an NAS birth was established prior to abstraction as ICD-9 code(s) 779.5 and/or 760.72. The exclusion criteria were admitted to neonatal intensive care immediately after birth, methadone not administered within 48 hours, and transfer to intensive care for complications or illness prior to completion of the treatment model. Analysis of outcomes related to health, safety, health services utilization, and cost was conducted. Descriptive statistics (frequency, percent, mean, median, range, and standard deviation [SD]) were generated using Stata 14 (StataCorp, College Station, Texas). Results are presented as mean (SD) if not otherwise indicated. Primary outcome measures included hospital length of stay; need for adjunctive medication; medical complications requiring transfer to a higher level of care; adverse medication and safety events; readmission rates; and total hospital charges, cost, and revenue per case.
Early Treatment Model Description
The early treatment model, developed in 2003, is based on the theory that neonates chronically exposed to long-acting opioids in late gestation are born in steady state. Research has demonstrated significant transfer of opioids across the placenta. 41 When started within 24 hours of birth, methadone social work, physical and occupational therapies, and child advocacy. The literature supports that 55 to 94% of neonates with chronic fetal exposure to long-acting opioids will experience clinically significant withdrawal. 21 For the small percentage of newborns who may receive unnecessary pharmacologic therapy under the early treatment model, the team decided to ensure that infants are formally screened for vital sign changes and symptoms of oversedation during hospitalization. The original model evolved over the course of a decade. Early changes included the development of preprinted order sets, changing a mandated 10-day stay for all at-risk newborns to a length of stay driven by medical need, an option for mothers to room-in for the entire newborn stay, and selection of methadone as the preferred pharmacotherapy to prevent severe opioid withdrawal. Additional changes included assignment of all newborns discharged on medication to one pediatric medical home for the duration of weaning, dispensing methadone in prefilled oral syringes, changing a requirement for caregivers to complete infant cardiopulmonary resuscitation (CPR) training prior to discharge to providing caregivers with formal education about safe sleeping environments, and recommending community-based infant CPR classes. Structure was added to the outpatient weaning process, with a target wean of 30 days and 15% dose reductions on prescribed days.
Currently, infants admitted to the mother/baby unit whose mothers are taking chronic long-acting opioids are offered early treatment, breast-feeding support (unless contraindicated), and extended stay for the hospitalization. Potential risks and benefits of early treatment are reviewed with parents; they are allowed to decline but are informed of symptom thresholds that will require pharmacotherapy during the birth hospitalization. All neonates deemed to be at risk for withdrawal are managed by a newborn hospitalist and receive low-stimulation supportive care. Infants exposed to maternal methadone doses of 60 mg or higher are started on 0.1 mg/kg/dose every 6 hours; those exposed to less methadone or buprenorphine are started on 0.05 mg/kg/dose every 6 hours. A pediatric pharmacist is involved with all cases for dosing recommendations and development of the weaning calendar. Urine and meconium drug screening and prescription monitoring database queries are routinely performed. To address the concern that a small percentage of neonates administered early methadone may be overtreated, continuous monitoring for apnea and bradycardia is performed in the mother's room to screen for low heart and respiratory rate, and modified Finnegan scoring and evaluation for oversedation is performed every 4 hours by trained mother/baby nursing staff. A social work evaluation is completed for all families. Any feeding supplementation, whether by maternal choice or physician order, is initiated with expressed breast milk or standard 0.67 kcal/mL formula.
Methadone dose adjustments are made for each patient based on all available evidence, including physician examination, nursing and parent reports, input from therapists, abstinence scores, weight loss, feeding and elimination patterns, and pediatric pharmacist recommendations. Scores alone do not drive dosing decisions. For suspected oversedation, continuous pulse oximetry is initiated, methadone is held until symptoms resolve, and then methadone is restarted at a lower dose or increased interval. For poor symptom control, methadone dosing is increased by 0.05 mg/kg approximately every 36 to 48 hours, to a maximum of 0.2 mg/kg/dose. Once abstinence scores are consistently eight or lower for 36 to48 hours, the methadone interval is changed to 8-hour dosing, maintaining the same total daily dose. After another 36 to 48 hours with stable scores, the methadone interval is changed to 12-hour dosing, maintaining the same total daily dose. After a final 36 to 48 hours with stable exams, scores, vital signs, and weight, the infant is discharged to an appropriate caregiver for outpatient weaning. All infants are discharged on methadone. A weaning calendar is developed by a pediatric pharmacist, and methadone is dispensed in prefilled oral syringes from the hospital outpatient pharmacy, which has an average out-of-pocket cost of $13. Caregivers are required to fill the prescription prior to discharge, and unit staff personnel reconcile that all needed syringes have been dispensed and that caregivers understand how to administer medication per the calendar. Apnea/bradycardia monitoring and abstinence scoring are discontinued at discharge. Dosage reductions of approximately 15% (of the discharge dose) occur every Sunday and Wednesday. Office visits occur at the outpatient pediatric medical home weekly during weaning to evaluate the effect of medication reduction. Outpatient physicians assess for signs or symptoms of poor NAS control and slow down the weaning process if necessary. One or two home nursing visits are provided through the regional health department office. Families are educated about signs of uncontrolled withdrawal that should prompt additional visits; they are not asked to do formal scoring. All newborns are referred for formal developmental assessment at 3 or 4 months as well as to phone-based parenting support and developmental screening services (Help Me Grow, Greenville, SC) that are available to up to age 8.
Results
From 2006 to 2014, early methadone treatment was provided for 143 infants within 48 hours of birth. After early methadone administration, 26 infants were transferred to neonatal intensive care for medical illness or complications including fever (n ¼ 10; 38%), hypoglycemia (n ¼ 7; 27%), respiratory distress (n ¼ 6; 23%), supraventricular tachycardia (n ¼ 1; 4%), bilious emesis (n ¼ 1; 4%), and feeding difficulty (n ¼ 1; 4%). In the level I nursery, 117 newborns completed the early treatment model. Cohort selection criteria are detailed in ►Fig. 1. ►Tables 1 and 2 outline the demographic and clinical characteristics of mothers and their newborns in the studied cohort. Data tables for maternal characteristics reflect each pregnancy or birth separately.
Mean gestational age for newborns was 39 (SD: 1.6) weeks; mean birthweight was 2,940 (SD: 465) g. Among mothers, mean age was 28 (SD: 5.2) years, and 97% of mothers received prenatal care, with a mean of 8.3 visits per pregnancy. Four planned adoptions occurred. More than half of mothers reported chronic mental health issues (►Table 2). The reported categories are not mutually exclusive; for example, 29 mothers experienced both depression and anxiety, and 11 mothers experienced bipolar disorder and anxiety.
Mothers taking buprenorphine reported an average daily dose of 14 (SD: 7) mg, and mothers taking methadone reported an average daily dose of 96 (SD: 50) mg. Mothers used medically assisted treatment for a variety of reasons: addiction to illegal substances (25%), addiction to nonprescribed opioids (46%), and dependence on/addiction to prescription opioids for acute (20%) or chronic pain (19%).
Maternal use of other drugs was measured through self-report as well as through infant urine and meconium drug screens. Illicit drug use during the third trimester triggered child protective services involvement but was not an exclusion criterion for the early treatment model. Nine (8%) mothers admitted illicit drug use after the first trimester. Newborn urine drug screens were confirmed positive for amphetamines in one infant and cocaine metabolites in two infants at delivery. Meconium drug screens were confirmed positive for amphetamines in one infant, methamphetamines in one infant, and cocaine metabolites in three infants. ►Table 3 summarizes medical and safety outcomes for newborns treated with the model. Forty-two percent in the cohort were fed breast milk; only 14 newborns required high-calorie supplementation. None experienced dehydration or a need for intravenous fluids. Adverse hospital events were infrequent; there were no medication errors and no deaths.
Seventy-five percent of patients met the targeted 30-day outpatient wean after its implementation during 2012. Seven patients visited the emergency department (ED) within 30 days of discharge and were not readmitted to the hospital. Two presented with symptoms possibly NAS-related: one medication issue and one diarrhea. Five of the discharged patients presented with symptoms not related to NAS; they were oral candidiasis, oral and diaper candidiasis, motor vehicle accident, minor head injury, and Listeria bacteremia (diagnosed after ED release). Nine patients were readmitted to the hospital within 30 days of discharge; six were for possible NAS-related issues, which included an event related to gastroesophageal reflux, feeding problems, failure to thrive, fever with NAS symptoms, and NAS symptoms alone. Three were readmitted for conditions not related to NAS: 
Discussion
Signs and symptoms of newborn opioid withdrawal have been well described in the literature and are consistent with phases of methadone withdrawal reported in adults.
19,21,39-41 After 1 to 3 days of abstinence, subjective symptoms of withdrawal include fatigue, nausea, craving, irritability, depression, muscle aches, and wakefulness. After 3 to 5 days of abstinence, severe symptoms and objective signs manifest, such as involuntary muscle spasms, arthralgias, muscle and bone pain, vomiting, diarrhea, insomnia, fever, sneezing, yawning, and agitation. In recent decades, increased attention has been given to preventing pain in neonates. According to the American Academy of Pediatrics (AAP), "The prevention of pain is important not only because it is an ethical expectation but also because repeated painful exposures can have deleterious consequences," including long-term disabilities. 32 In addition, the AAP reports that "early and effective pain treatment is associated with a lower total dose of medication" and fears that analgesics (especially opioids) may lead to hypotension or respiratory depression has never been confirmed in randomized controlled trials. 32 According to Anand regarding the management of mild to moderate pain in neonates, "The use of environmental therapies (swaddling, sucrose, pacifiers) and decreased stimuli have limited therapeutic efficacy." 33 No reported treatment models for NAS have focused on the prevention of suffering associated with the experience. In contrast, experts to date have emphasized that newborn withdrawal is "a self-limited process" and have de-emphasized the importance of treating suffering until clearly measurable.
32
The concept of weaning pediatric patients with opioid dependence is not new. For those requiring prolonged life support and opioid therapy, standard practice is to wean opioids slowly over days to weeks to avoid the experience of withdrawal and symptoms that may confuse a complex medical course. Until now, this concept applied to fetal opioid dependence has never been studied.
While NAS treatment commonly occurs in the intensive care setting, 3 there has been increased interest in lower-acuity Abbreviation: SSRI, selective serotonin reuptake inhibitor. Note: A cohort of 108 mothers gave birth to 117 studied infants. One mother had twins, and eight mothers had two infants at different times during the study period. White mothers were 96%, 71% completed high school, and 38% were married. The 8.3-day mean hospital stay for our sample was less than half of that reported nationally for all NAS infants (mean: 16.9 days) 2 and was approximately one-third the hospital stay for pharmacologically treated NAS infants (mean: 23 days).
2
Despite the significant reduction in stay, adverse safety and medical events for our studied cohort were low. Lee et al reported similar low rates of complication for a combined inpatient/outpatient model.
42
In the studied cohort, early treatment for newborns with significant opioid exposure during late gestation promoted early control of NAS symptoms without excessive risk of oversedation. Appropriate monitoring was effectively accomplished in a low-acuity setting; there were no reports of oversedation after discharge.
Patients displayed peak NAS symptoms consistent with the timing reported in other studies. 3, [19] [20] [21] [36] [37] [38] The researchers hypothesize that early treatment kept newborns from entering severe opioid withdrawal, when most gastrointestinal symptoms manifest. The average infant did not experience significant feeding problems, excessive weight loss, diarrhea, dehydration, or severe perianal maceration, 13 While our study did not include a matched cohort for comparison, further analysis of state data to identify a comparison group with the same exclusion criteria is being performed and will be reported in a future publication. Our study demonstrates that pharmacologic treatment can be provided in a combined inpatient/outpatient setting that results in reduced length of stay, maternal-infant separation, and cost, without sacrificing safety or readmission rates. Strengths of the current study included a consistent and stable provider team over the course of model utilization, development of a database for tracking adverse events and related medical outcomes, and having an outpatient medical home willing to provide standardized care for all discharged patients. Potential limitations of this study included lack of a control group, low numbers of neonates qualifying for the early treatment protocol, adjustments made to the treatment protocol over time, and an inability to define total opioid exposure levels for the cohort. Of these, the most important limitation was the fact that minor adjustments were made to the treatment protocol over time. For example, standardized weaning of 30 days or less was not implemented until 2012. Prior to 2012, the pharmacists were not directed to limit the length of the outpatient wean. As a result, the average duration of treatment for the cohort was longer than the duration for infants being treated with the model today. There were several cases of suspected medication mishandling during the early years of our treatment protocol, all of which occurred when newborns were sent home with medication in a multidose bottle. Such events did not occur after the change to dispensing prefilled oral syringes. Although protocol changes had the potential to impact results, the changes were each designed to improve the quality of care and address protocol weaknesses that were observed over time. A barrier to replication of our treatment model may be a variation in state laws related to allowable methadone prescribing.
Future research may include a prospective study with a comparison group to determine the effectiveness of this intervention in other regional hospitals with low-acuity nurseries. If similar results are demonstrated, the model may be a safe and effective tool for improving clinical outcomes for newborns diagnosed with NAS. In addition, maintaining a database of newborns with mild to moderate NAS who were treated with early methadone may allow for future reporting of associated long-term medical, developmental, and family outcomes.
Conclusion
This study is the first to describe an approach to preventing severe newborn opioid withdrawal using an early treatment model. New models of care for NAS are needed; approaches shown to be safe, effective, ethical, and economical have widespread applicability. Establishing a viable model of care for NAS treatment in low-acuity nurseries will provide economic and social benefits to this unique population of patients in our community, state, and nation. Demonstrating a reduction in health care costs using our model could impact health policy and professional guidelines yet to be developed. Further, our model is family-and patient-centered, promoting education, engagement, and empowerment of families during the course of treatment. It is hoped that in the long term, the model will impact overall family success.
